| Literature DB >> 26506444 |
Thi-Phuong-Lan Nguyen1, Paul F M Krabbe2, Thi-Bach-Yen Nguyen3, Catharina C M Schuiling-Veninga1, E Pamela Wright4, Maarten J Postma5.
Abstract
OBJECTIVES: The study aims to inform potential cost-effectiveness analysis of hypertension management in Vietnam by providing utilities and predictors of utilities in patients with hypertension.Entities:
Mesh:
Year: 2015 PMID: 26506444 PMCID: PMC4623979 DOI: 10.1371/journal.pone.0139560
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of patients included in the study (n = 712).
| Characteristics | Number (%) |
|---|---|
|
| |
| 41–49 | 12 (1.7) |
| 50–59 | 142 (19.9) |
| 60–69 | 367 (51.5) |
| 70–80 | 191 (26.8) |
|
| |
| Male | 314 (44.1) |
|
| |
| Being retired or doing housework | 637 (89.5) |
| Working and earning money | 75 (10.5) |
|
| |
| Kinh | 651 (91.4) |
| Others | 61 (8.6) |
|
| |
| Target-BP | 242 (34.0) |
| Stage one | 360 (50.6) |
| Stage two | 110 (15.4) |
|
| |
| Comorbidity(ies) | 500 (70.2) |
|
| |
| History of stroke | 78 (11) |
|
| |
| Health-state utility (mean +/- SD (n = 691) | 0.73 (+/- 0.14) |
Note: Health utility was calculated in 691 patients, as syntax of transferring SF-36 data to utility did not work in 21 cases (3%) with missing value of any one of the items in the SF-36 form.
Distribution of health-state utilities by patients’ characteristic (n = 691).
| Characteristics | Mean | Standard deviation | P value |
|---|---|---|---|
|
| 0.004 | ||
| 41–49 | 0.787 | 0.16 | |
| 50–59 | 0.749 | 0.14 | |
| 60–69 | 0.730 | 0.14 | |
| 70–80 | 0.700 | 0.13 | |
|
| 0.005 | ||
| Male | 0.743 | 0.14 | |
| Female | 0.713 | 0.14 | |
|
| 0.422 | ||
| Target-BP | 0.734 | 0.14 | |
| Stage one | 0.726 | 0.13 | |
| Stage two | 0.712 | 0.15 | |
|
| 0.717 | ||
| No comorbidity | 0.729 | 0.14 | |
| Comorbidity(ies) | 0.725 | 0.14 | |
|
| 0.729 | ||
| No stroke | 0.727 | 0.14 | |
| Stroke | 0.721 | 0.15 |
Predictors of health-state utilities in hypertensive patients (n = 691).
| OR | 95% CI | p | ||
|---|---|---|---|---|
| Lower bound | Upper bound | |||
|
| ||||
| 41–49 (ref) | ||||
| 50–59 | -0.04 | -0.12 | 0.04 | 0.34 |
| 60–69 | -0.06 | -0.13 | 0.02 | 0.16 |
| 70–80 | -0.09 | -0.17 | -0.01 | 0.03 |
|
| ||||
| Male (ref) | ||||
| Female | -0.03 | -0.05 | -0.01 | 0.002 |
|
| ||||
| Target-BP (ref) | ||||
| BP Stage one | -0.01 | -0.03 | 0.01 | 0.43 |
| BP stage two | -0.02 | -0.05 | 0.02 | 0.32 |
|
| ||||
| No history of stroke (ref) | ||||
| History of stroke | -0.004 | -0.04 | 0.03 | 0.79 |
|
| ||||
| No comorbidity (ref) | ||||
| One comorbidity | 0.01 | -0.02 | 0.03 | 0.53 |
| Two comorbidities | -0.004 | -0.03 | 0.03 | 0.81 |
| Three comorbidities | -0.04 | -0.08 | 0.02 | 0.20 |
| > Three comorbidities | -0.11 | -0.18 | -0.03 | 0.01 |